All Access

Health Tech Deals

Health Tech Deals Alerts

Alert

Standard

Health Tech Deals Thought Bubble

Thought Bubble

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

pittsburgh

atlanta

san-diego

charlotte

boulder

washington-dc

kansas-city

dallas

denver

detroit

des-moines

austin

boston

chicago

cleveland

columbus

houston

indianapolis

miami

nashville

new-orleans

nw-arkansas

philadelphia

phoenix

portland

richmond

salt-lake-city

san-antonio

san-francisco

seattle

tampa-bay

twin-cities

raleigh

huntsville

colorado-springs

axios-local

axios-pro

axios-live

the-axios-show

ArteraAI, a developer of AI tests to personalize therapy for cancer patients, raised $20 million in additional funding, CEO Andre Esteva tells Axios exclusively.

Why it matters: Rising cancer costs have made personalized treatment modalities and their promise of cost savings more appealing.

Details: Participants included Prosperity7 Ventures, Singapore's EDBI and insiders Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, and Trium Ventures.

Plus individuals Navin Chaddha (Mayfield), Rajiv Khemani (AISpace VC), and Andrew & Elliott Tan (A&E Investment). There was no lead investor for the unlabeled round.

The Los Altos, Calif.-based company has raised more than $100 million in outside capital, including $90 million in March 2023.

What's next: "We want to be one of the first tests to support cancer personalization in other countries," Esteva says.

ArteraAI is targeting Europe and Asia Pacific first, he says.

The company's test — currently for prostate cancer — will be further developed to address breast cancer, with the eventual goal of serving all forms of the disease, he says.

How it works: ArteraAI's multimodal AI test — reimbursed by Medicare as of this year — identifies patients who will benefit from intensified therapy, and guides treatment for localized patients.

Once ArteraAI receives a sample, the company reports back to the referring oncologist within 2-3 days with treatment guidance.

What they're saying: "The fast and accurate result, now combined with the reimbursement approval — the company is poised to really take off," says Walden Catalyst Ventures managing partner Lip-Bu Tan.

"There is a global opportunity here," Tan says.

Exclusive: ArteraAI nabs $20M to take personalized cancer care global

As cancer care costs rise, personalized treatment modalities have become increasingly vital

Illustration of hundred dollar bills and coins arranged in the shape of a cancer ribbon.

Health tech deals

ArteraAI, a developer of AI tests to personalize therapy for cancer patients, raised $20 million in additional funding, CEO Andre Esteva tells Axios exclusively.Why it matters: <a class="gtmContentClick" data-vars-link-text="Rising cancer costs" data-vars-click-url="https://link.axios.com/click/34200541.630/aHR0cHM6Ly93d3cuYXhpb3MuY29tLzIwMjIvMDQvMTkvY2FuY2VyLXByZXNjcmlwdGlvbi1kcnVnLXByaWNlcy1ob3NwaXRhbHM_dXRtX3NvdXJjZT1uZXdzbGV0dGVyJnV0bV9tZWRpdW09ZW1haWwmdXRtX2NhbXBhaWduPXByb19kZWFsc19oZWFsdGh0ZWNoX3N1YnMmc3RyZWFtPXRvcA/63d7efa24889932dcb08ba1cB679e27df" data-vars-content-id="f119eaf9-b6b1-4106-8e1d-42e0807fc281" data-vars-headline="Exclusive: ArteraAI nabs $20M to take personalized cancer care global" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://link.axios.com/click/34200541.630/aHR0cHM6Ly93d3cuYXhpb3MuY29tLzIwMjIvMDQvMTkvY2FuY2VyLXByZXNjcmlwdGlvbi1kcnVnLXByaWNlcy1ob3NwaXRhbHM_dXRtX3NvdXJjZT1uZXdzbGV0dGVyJnV0bV9tZWRpdW09ZW1haWwmdXRtX2NhbXBhaWduPXByb19kZWFsc19oZWFsdGh0ZWNoX3N1YnMmc3RyZWFtPXRvcA/63d7efa24889932dcb08ba1cB679e27df" target="_self">Rising cancer costs</a> have made <a class="gtmContentClick" data-vars-link-text="personalized treatment modalities" data-vars-click-url="https://link.axios.com/click/34200541.630/aHR0cHM6Ly93d3cuY2FuY2VyLm9yZy9jYW5jZXIvbWFuYWdpbmctY2FuY2VyL3RyZWF0bWVudC10eXBlcy9wcmVjaXNpb24tbWVkaWNpbmUuaHRtbD91dG1fc291cmNlPW5ld3NsZXR0ZXImdXRtX21lZGl1bT1lbWFpbCZ1dG1fY2FtcGFpZ249cHJvX2RlYWxzX2hlYWx0aHRlY2hfc3VicyZzdHJlYW09dG9w/63d7efa24889932dcb08ba1cBdeb91b41" data-vars-content-id="f119eaf9-b6b1-4106-8e1d-42e0807fc281" data-vars-headline="Exclusive: ArteraAI nabs $20M to take personalized cancer care global" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://link.axios.com/click/34200541.630/aHR0cHM6Ly93d3cuY2FuY2VyLm9yZy9jYW5jZXIvbWFuYWdpbmctY2FuY2VyL3RyZWF0bWVudC10eXBlcy9wcmVjaXNpb24tbWVkaWNpbmUuaHRtbD91dG1fc291cmNlPW5ld3NsZXR0ZXImdXRtX21lZGl1bT1lbWFpbCZ1dG1fY2FtcGFpZ249cHJvX2RlYWxzX2hlYWx0aHRlY2hfc3VicyZzdHJlYW09dG9w/63d7efa24889932dcb08ba1cBdeb91b41" target="_self">personalized treatment modalities</a> and their promise of cost savings more appealing.

Exclusive: ArteraAI nabs $20M to take personalized cancer care global

What to read next